| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | vWA1 |
| Uniprot No | Q6PCB0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-445aa |
| 氨基酸序列 | ERGPPASA PRGDLMFLLD SSASVSHYEF SRVREFVGQL VAPLPLGTGA LRASLVHVGS RPYTEFPFGQ HSSGEAAQDA VRASAQRMGD THTGLALVYA KEQLFAEASG ARPGVPKVLV WVTDGGSSDP VGPPMQELKD LGVTVFIVST GRGNFLELSA AASAPAEKHL HFVDVDDLHI IVQELRGSIL DAMRPQQLHA TEITSSGFRL AWPPLLTADS GYYVLELVPS AQPGAARRQQ LPGNATDWIW AGLDPDTDYD VALVPESNVR LLRPQILRVR TRPGEAGPGA SGPESGAGPA PTQLAALPAP EEAGPERIVI SHARPRSLRV SWAPALGSAA ALGYHVQFGP LRGGEAQRVE VPAGRNCTTL QGLAPGTAYL VTVTAAFRSG RESALSAKAC TPDGPRPRPR PVPRAPTPGT ASREP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与vWA1重组蛋白相关的模拟参考文献(注：文献信息为示例性虚构，实际需检索数据库获取)：
---
1. **文献名称**: *Structural Insights into the vWA1 Domain-Mediated Protein Interactions*
**作者**: Zhang Y, et al.
**摘要**: 本研究通过X射线晶体学解析了重组vWA1蛋白的三维结构，揭示其与整合素结合的分子机制，为设计靶向细胞粘附的抑制剂提供理论依据。
2. **文献名称**: *Recombinant vWA1 Protein Attenuates Inflammation in a Murine Sepsis Model*
**作者**: Li X, et al.
**摘要**: 利用大肠杆菌表达系统制备高纯度重组vWA1蛋白，实验证明其通过抑制TLR4/NF-κB通路显著降低内毒素诱导的小鼠全身性炎症反应。
3. **文献名称**: *Functional Characterization of vWA1 in Tumor Angiogenesis*
**作者**: Wang H, et al.
**摘要**: 研究发现重组vWA1蛋白通过结合VEGF受体调控血管生成，siRNA敲低vWA1可抑制肿瘤内皮细胞迁移，提示其作为抗肿瘤治疗靶点的潜力。
4. **文献名称**: *Optimization of Recombinant vWA1 Expression in HEK293 Cells*
**作者**: Patel R, et al.
**摘要**: 通过优化培养条件和密码子偏好性，在HEK293细胞中实现重组vWA1蛋白的高效分泌表达，为大规模生产提供可靠方案。
---
建议通过PubMed或Web of Science以关键词"vWA1 recombinant protein"或"von Willebrand A domain protein 1"检索真实文献。
**Background of vWA1 Recombinant Protein**
The von Willebrand factor A domain-containing protein 1 (vWA1) is a conserved extracellular matrix (ECM)-associated protein implicated in cell adhesion, signaling, and tissue homeostasis. Its name derives from the presence of a von Willebrand factor type A (vWA) domain, a structural motif known for mediating protein-protein interactions, particularly with integrins and collagen. vWA1 is expressed in various tissues, including the nervous system, skeletal muscle, and connective tissues, suggesting roles in development, regeneration, and disease processes.
Recombinant vWA1 protein is engineered through genetic cloning, where the *VWA1* gene is inserted into expression vectors (e.g., bacterial, mammalian, or insect systems) to produce purified, functional protein. This approach allows controlled study of vWA1's biochemical properties, such as its binding affinity for integrins (e.g., αvβ3. α4β1) or ECM components, and its influence on cellular behaviors like migration, proliferation, and differentiation.
Research highlights vWA1's dual role in health and disease. In normal physiology, it supports tissue repair and neural network formation. However, dysregulation of vWA1 is linked to pathologies, including fibrosis, neurodegenerative disorders, and cancer metastasis. For example, elevated vWA1 expression in tumors may promote invasiveness by enhancing ECM remodeling and cell-ECM communication.
The development of recombinant vWA1 has enabled therapeutic exploration, such as designing inhibitors to block its pathological interactions or using it as a scaffold in regenerative medicine. Its study also aids in deciphering ECM dynamics, offering insights into broader mechanisms of tissue organization and disease progression. Overall, vWA1 recombinant protein serves as a critical tool for both basic research and translational applications.
×
